“In an interview with Barron’s, Narasimhan said some of the programs which Novartis discontinued were cancer drugs in early-stage trials.
“We saw assets that were noncompetitive, or we thought might be unduly affected by IRA,” Narasimhan said.
The CEO said “a few” of the cancer drugs being dropped from Novartis’s pipeline were discontinued because of price negotiations.
The drugs that were dropped were “in areas where we didn’t think we could do a development plan that would allow us to successfully get the drug in patients, and fully developed across the range of indications within nine years,” Narasimhan said. They were in cancers particularly affecting the elderly, given that Medicare treats adults aged 65 and older.”
2 Discontinued Drugs: unnamed cancer drugs
2 Discontinued Research Programs
